colorectal cancer
Conditions
Interventions
Experiment group:Kangai injection 60ml ivgtt D1-14 Q21d, combined with chemotherapy: Eloxatin 130mg/m2 2h ivgtt d1, Xeloda 1000mg/m2 bid po d1-14 Q21d
Control group:Chemotherapy: Eloxatin 130mg/m2 2h ivgtt d1, Xeloda 1000mg/m2 bid po d1-14 Q21d
Sponsors
Guang'anmen Hospital affiliatied to China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Postoperative or inoperable Colorectal Cancer patients, at stage II, III, IV, need chemotherapy XELOX; 2. ECOG score 0-1; 3. Aged from 18 to 75 years old; 4. ANC>1.5*10^9/L, PLT>100*10^9/L, Hb>9.0g/dl, BIL Colorectal Cancerat normal level or < 1.5 x ULN, AST (SGOT), ALT (SGPT) < 2.5 x ULN; SCr< 1.5 x ULN; 5. Signed informed consent, with good compliance.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. psychotic patient; 3. Patients with severe,uncontrolled organic lesions or infection, such as decompensated heart, lung, kidney failure can lead to tolerance of chemotherapy; 4. using other experimental drugs or paticipate in other clinical trials at the same time; 5. patients allergic to the investigational product; 6. patients undergoing radiotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse Reactions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical Symptoms,Quality of Life,KPS Score Immunologic Function, Tumor Marker, Passing Rate of Chemotherapy; | — |
Countries
China
Contacts
Public ContactHongsheng Lin
Guang'anmen Hospital affiliatied to China Academy of Chinese Medical Sciences
Outcome results
None listed